In this study, we developed DB-1310, an anti-HER3 ADC conjugating with a novel HER3 antibody and proprietary DNA topoisomerase I inhibitor payload (P1021), investigated its mechanism of action and preclinically evaluated its efficacy in breast, NSCLC, colon and prostate cancer models. The gene discussed is ERBB3; the disease is non-small cell lung carcinoma.